phive2015
William Blair has started coverage of RayzeBio (NASDAQ:RYZB) with a buy rating, commenting that the company is “poised to become a leader” in radiopharmaceuticals.
The investment bank said it sees RayzeBio’s lead therapy candidate, RYZ101, which is in Phase 3 testing for neuroendocrine tumors, as having a “high chance of success,” while testing for small-cell lung cancer could provide an “expansion path” for its RYZ101 franchise. It added that the therapy could become the first approved actinium-225-based radiopharmaceutical.
William Blair also thinks the company’s move to produce and radiolabel actinium-225 in-house while maintaining external supply agreements “incorporates redundancy into the supply chain and may help ensure a consistent source of radiopharmaceuticals” for both clinical and commercial purposes.
“We believe that full in-house production is a differentiating feature among clinical-stage radiopharmaceutical companies,” the bank added.